SUPPLY AGREEMENT BY AND BETWEEN BAYER HEALTHCARE LLC BIOLOGICAL PRODUCTS DIVISION BERKELEY, CALIFORNIA AND TALECRIS BIOTHERAPEUTICS, INC. RALEIGH, NORTH CAROLINASupply Agreement • July 23rd, 2008 • Talecris Biotherapeutics Holdings Corp. • Pharmaceutical preparations • New York
THIS SUPPLY AGREEMENT (this “Agreement”) is entered into as of March 31, 2005 (the “Effective Date”), by and between Bayer HealthCare LLC, Biological Products Division (“Bayer”) and Talecris Biotherapeutics, Inc. (f/k/a NPS BioTherapeutics, Inc.) (“Supplier,” along with Bayer, the “Parties”).
CONTRACT FRACTIONATION SERVICES AND COMMERCIAL PRODUCTS AGREEMENTContract Fractionation Services and Commercial Products Agreement • July 23rd, 2008 • Talecris Biotherapeutics Holdings Corp. • Pharmaceutical preparations • Ontario
NOW THEREFORE in consideration of the premises, covenants and agreements contained herein and other valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:
Talecris BiotherapeuticsTalecris Biotherapeutics Holdings Corp. • July 23rd, 2008 • Pharmaceutical preparations
As you know, Talecris Biotherapeutics (“Talecris”) has agreed to purchase Bayer’s Plasma Business. When the purchase is completed (the “Closing”) we want you to be a part of the Talecris team. The purpose of this letter is to confirm the basic terms of your employment with Talecris.
MASTER CONSULTING AND ADVISORY SERVICES AGREEMENTMaster Consulting and Advisory Services Agreement • July 23rd, 2008 • Talecris Biotherapeutics Holdings Corp. • Pharmaceutical preparations • New York
THIS MASTER CONSULTING AND ADVISORY SERVICES AGREEMENT (the “Agreement”) is made and entered into effective as of this 18th day of July, 2008 (the “Effective Date”), by and between CERBERUS OPERATIONS AND ADVISORY COMPANY LLC, a Delaware limited liability company with offices at 299 Park Avenue, New York, New York 10171 (“COAC”), and TALECRIS BIOTHERAPEUTICS HOLDINGS CORP., a Delaware corporation, with offices at 4101 Research Commons, 79 T.W. Alexander Drive, Research Triangle Park, North Carolina 27709, on behalf of itself and any of its wholly owned subsidiaries which may sign and Engagement Letter as hereinafter defined (“Talecris”). For purposes of this Agreement, COAC and Talecris each may be referred to individually as a “Party” and together, as the “Parties”.
AGREEMENT ***TEXT OMITTED AND SUBMITTED SEPARATELY PURSUANT TO CONFIDENTIAL TREATMENT REQUEST UNDER 17 C.F.R. SECTIONS 200.80(b)(4) AND 230.406 BETWEEN AND AMONGST HÉMA-QUÉBEC AND TALECRIS BIOTHERAPEUTICS LTD. AND TALECRIS BIOTHERAPEUTICS INC.Fractionation Services and Commercial Products Agreement • July 23rd, 2008 • Talecris Biotherapeutics Holdings Corp. • Pharmaceutical preparations • Ontario
NOW THEREFORE in consideration of the premises, covenants and agreements contained herein and other valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:
MANUFACTURING AGREEMENT BY AND BETWEEN BAYER HEALTHCARE LLC BIOLOGICAL PRODUCTS DIVISION BERKELEY, CALIFORNIA AND TALECRIS BIOTHERAPEUTICS, INC. RALEIGH, NORTH CAROLINAManufacturing Agreement • July 23rd, 2008 • Talecris Biotherapeutics Holdings Corp. • Pharmaceutical preparations • New York
This MANUFACTURING AGREEMENT (this “Agreement”) is entered into as of March 31, 2005 (the “Effective Date”) by and between Talecris Biotherapeutics, Inc. (f/k/a NPS BioTherapeutics, Inc.) (“Purchaser”) and Bayer HealthCare LLC, Biological Products Division (“Bayer,” along with Purchaser, the “Parties”).
THIS DOCUMENT AFFECTS IMPORTANT LEGAL RIGHTS. TAKE IT HOME AND READ IT CAREFULLY BEFORE YOU SIGN IT. YOU ARE ADVISED TO CONSULT WITH AN ATTORNEY OF YOUR CHOICE BEFORE SIGNING THE DOCUMENT. SEPARATION AGREEMENT AND GENERAL CLAIMS RELEASESeparation Agreement and General Claims Release • July 23rd, 2008 • Talecris Biotherapeutics Holdings Corp. • Pharmaceutical preparations
This Separation Agreement and General Claims Release (hereinafter referred to as “Agreement”) is made and entered into by and between Alberto Martinez (hereinafter referred to as “Employee”) and Talecris Biotherapeutics Holdings Corp., a Delaware corporation authorized to do business in the State of North Carolina, its past and present owners, subsidiaries, affiliates, successors, predecessors and assigns (hereinafter referred to as “the Company”).
EUROPEAN PRODUCT SALES AGREEMENT (PHASE I) BY AND BETWEEN BAYER BIOLOGICALS S.R.L. MILAN, ITALY AND TALECRIS BIOTHERAPEUTICS, GMBH FRANKFURT, GERMANYEuropean Product Sales Agreement • July 23rd, 2008 • Talecris Biotherapeutics Holdings Corp. • Pharmaceutical preparations
